Celltrion Group develops, produces, and sells biosimilar, It currently possesses and sells three products – Remsima™ (Remicade), Herzuma™ (Herceptin), and Truxima™ (Rituximab) – in the US and Europe region. Celltrion started as a biosimilar CDMO company and is responsible for the development and production of biosimilar pipelines of the Celltrion Group. Celltrion Healthcare is in charge of global licensing and sales of products. IMM participated in early R&D funding for long-term, large-scale clinical trials of Celltrion.